Details of the Drug Combination

General Information of Drug Combination (ID: DC173WM)

• Drug Combination Name: Lorazepam + Haloperidol
• Indication: Methamphetamine Intoxication (Disorder); Status: Phase 2 [1]
• Component Drugs:
  Lorazepam (DM84ZXF): Small molecular drug
  Haloperidol (DM96SE0): Small molecular drug

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Lorazepam

Disease Entry	ICD 11	Status	REF
Absence epilepsy	N.A.	Approved	[2]
Anxiety	N.A.	Approved	[2]
Anxiety disorder	6B00-6B0Z	Approved	[3]
Nausea	MD90	Approved	[2]
Panic disorder	6B01	Approved	[2]
Vomiting	MD90	Approved	[2]

Lorazepam Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Modulator	[7]

Lorazepam Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Metabolism	[8]
UDP-glucuronosyltransferase 2B15 (UGT2B15)	DENZ6B1	UDB15_HUMAN	Metabolism	[9]

Indication(s) of Haloperidol

Disease Entry	ICD 11	Status	REF
Delirium	N.A.	Approved	[4]
Nausea	MD90	Approved	[4]
Psychotic disorder	6A20-6A25	Approved	[4]
Schizophrenia	6A20	Approved	[5]
Vomiting	MD90	Approved	[4]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[6]
Tourette syndrome	8A05.00	Investigative	[4]

Haloperidol Interacts with 3 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Antagonist	[13]
HUMAN opioid receptor sigma 1 (OPRS1)	TTTPE1L	SGMR1_HUMAN	Modulator	[14]
HUMAN sigma intracellular receptor 2 (TMEM97)	TTIS0R2	SGMR2_HUMAN	Modulator	[14]

Haloperidol Interacts with 1 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[15]

Haloperidol Interacts with 9 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Metabolism	[17]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Metabolism	[17]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[18]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[16]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Metabolism	[19]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[17]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Metabolism	[17]
UDP-glucuronosyltransferase 1A9 (UGT1A9)	DE85D2P	UD19_HUMAN	Metabolism	[20]

Haloperidol Interacts with 129 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Affects Response To Substance	[21]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Decreases Expression	[22]
D(1A) dopamine receptor (DRD1)	OTLZPBT7	DRD1_HUMAN	Affects Activity	[23]
D(4) dopamine receptor (DRD4)	OTAJTO7N	DRD4_HUMAN	Affects Activity	[23]
Brain-derived neurotrophic factor (BDNF)	OTLGH7EW	BDNF_HUMAN	Increases Expression	[24]
D(3) dopamine receptor (DRD3)	OT0OFFKB	DRD3_HUMAN	Affects Binding	[25]
Superoxide dismutase (SOD1)	OT39TA1L	SODC_HUMAN	Increases ADR	[26]
Catalase (CAT)	OTHEBX9R	CATA_HUMAN	Increases ADR	[26]
G protein-activated inward rectifier potassium channel 1 (KCNJ3)	OTHQG16J	KCNJ3_HUMAN	Increases ADR	[26]
Glutathione S-transferase P (GSTP1)	OTLP0A0Y	GSTP1_HUMAN	Decreases Expression	[22]
Multidrug resistance-associated protein 1 (ABCC1)	OTGUN89S	MRP1_HUMAN	Decreases Expression	[22]
Stearoyl-CoA desaturase (SCD)	OTB1073G	SCD_HUMAN	Increases Expression	[27]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Increases Expression	[27]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Increases Expression	[27]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1)	OTCO26FV	HMCS1_HUMAN	Increases Expression	[27]
Lathosterol oxidase (SC5D)	OT41KMW4	SC5D_HUMAN	Increases Expression	[28]
Low-density lipoprotein receptor (LDLR)	OTH559LU	LDLR_HUMAN	Increases Expression	[28]
Nuclear protein 1 (NUPR1)	OT4FU8C0	NUPR1_HUMAN	Increases Expression	[10]
Alpha-1-antichymotrypsin (SERPINA3)	OT9BP2S0	AACT_HUMAN	Increases Expression	[10]
Asparagine synthetase (ASNS)	OT8R922G	ASNS_HUMAN	Decreases Expression	[10]
Inhibin beta E chain (INHBE)	OTOI2NYG	INHBE_HUMAN	Increases Expression	[10]
Transgelin (TAGLN)	OTAEZ0KP	TAGL_HUMAN	Decreases Expression	[10]
Nuclear receptor subfamily 0 group B member 2 (NR0B2)	OT7UVICX	NR0B2_HUMAN	Increases Expression	[10]
Lysophospholipase D GDPD3 (GDPD3)	OTOHM9QM	GDPD3_HUMAN	Increases Expression	[10]
Fibronectin type III domain-containing protein 4 (FNDC4)	OTOQK0WK	FNDC4_HUMAN	Increases Expression	[10]
Protein DEPP1 (DEPP1)	OTB36PHJ	DEPP1_HUMAN	Increases Expression	[10]
AP-3 complex subunit beta-1 (AP3B1)	OTYTIH5Q	AP3B1_HUMAN	Increases Expression	[11]
Importin subunit alpha-3 (KPNA4)	OTP0EX18	IMA3_HUMAN	Increases Expression	[11]
Branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2)	OT8L6EGI	BCAT2_HUMAN	Decreases Expression	[11]
Transmembrane protease serine 2 (TMPRSS2)	OTN44YQ5	TMPS2_HUMAN	Increases Expression	[29]
Period circadian protein homolog 1 (PER1)	OTVQF3WX	PER1_HUMAN	Increases Expression	[30]
Kinesin heavy chain isoform 5C (KIF5C)	OT35570Y	KIF5C_HUMAN	Decreases Expression	[11]
Copine-3 (CPNE3)	OTCR3WG2	CPNE3_HUMAN	Decreases Expression	[11]
CCR4-NOT transcription complex subunit 3 (CNOT3)	OT4D5Z9L	CNOT3_HUMAN	Decreases Expression	[11]
Pyridoxal phosphate homeostasis protein (PLPBP)	OT9DZ8P6	PLPHP_HUMAN	Increases Expression	[11]
Prolactin (PRL)	OTWFQGX7	PRL_HUMAN	Increases Expression	[31]
Fatty acid-binding protein, heart (FABP3)	OT562DA1	FABPH_HUMAN	Increases Expression	[11]
Prothymosin alpha (PTMA)	OT2W4T1M	PTMA_HUMAN	Increases Expression	[11]
Corticoliberin (CRH)	OT2MOC4T	CRF_HUMAN	Decreases Expression	[32]
Profilin-1 (PFN1)	OTHTGA1H	PROF1_HUMAN	Increases Expression	[11]
Signal recognition particle receptor subunit alpha (SRPRA)	OT5NMYTY	SRPRA_HUMAN	Decreases Expression	[11]
Stromelysin-2 (MMP10)	OTJDWW8Q	MMP10_HUMAN	Decreases Expression	[11]
Glycogen phosphorylase, muscle form (PYGM)	OTWLVWTV	PYGM_HUMAN	Decreases Expression	[11]
Histidine--tRNA ligase, cytoplasmic (HARS1)	OTHOEOTS	HARS1_HUMAN	Increases Expression	[11]
Plastin-3 (PLS3)	OTYBM4PK	PLST_HUMAN	Decreases Expression	[11]
Glial fibrillary acidic protein (GFAP)	OTQ01ZAS	GFAP_HUMAN	Decreases Expression	[11]
Solute carrier family 2, facilitated glucose transporter member 4 (SLC2A4)	OTJZG0LD	GLUT4_HUMAN	Increases Expression	[33]
Ezrin (EZR)	OTHBPF1Z	EZRI_HUMAN	Decreases Expression	[11]
V-type proton ATPase subunit B, kidney isoform (ATP6V1B1)	OT8FQ7MN	VATB1_HUMAN	Decreases Expression	[11]
Probable ATP-dependent RNA helicase DDX5 (DDX5)	OTLS124U	DDX5_HUMAN	Decreases Expression	[11]
Vascular endothelial growth factor receptor 1 (FLT1)	OTT0OGYS	VGFR1_HUMAN	Decreases Expression	[11]
Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PCMT1)	OTGYVSGU	PIMT_HUMAN	Decreases Expression	[11]
Cofilin-1 (CFL1)	OTT6D5MH	COF1_HUMAN	Increases Expression	[11]
Acetyl-CoA acetyltransferase, mitochondrial (ACAT1)	OTJC60Q7	THIL_HUMAN	Decreases Expression	[11]
5-hydroxytryptamine receptor 2A (HTR2A)	OTWXJX0M	5HT2A_HUMAN	Affects Binding	[34]
General transcription factor IIE subunit 1 (GTF2E1)	OTAG9V0I	T2EA_HUMAN	Decreases Expression	[11]
Stress-induced-phosphoprotein 1 (STIP1)	OT7TXLOX	STIP1_HUMAN	Decreases Expression	[11]
Catenin alpha-1 (CTNNA1)	OTFC725Z	CTNA1_HUMAN	Decreases Expression	[11]
Radixin (RDX)	OTNSYUN6	RADI_HUMAN	Decreases Expression	[11]
Vascular endothelial growth factor receptor 2 (KDR)	OT15797V	VGFR2_HUMAN	Increases Expression	[11]
Transgelin-2 (TAGLN2)	OTUXZGDQ	TAGL2_HUMAN	Decreases Expression	[11]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA)	OTIOLNHE	LICH_HUMAN	Increases Expression	[11]
Pituitary adenylate cyclase-activating polypeptide type I receptor (ADCYAP1R1)	OTNBHULA	PACR_HUMAN	Affects Expression	[12]
Small ribosomal subunit protein eS27 (RPS27)	OTFXKY7P	RS27_HUMAN	Increases Expression	[11]
Cell surface glycoprotein MUC18 (MCAM)	OTT8XKGE	MUC18_HUMAN	Increases Expression	[11]
Vesicle-fusing ATPase (NSF)	OTKRJ2ZT	NSF_HUMAN	Decreases Expression	[11]
Serine--tRNA ligase, cytoplasmic (SARS1)	OTFKXQ1O	SYSC_HUMAN	Decreases Expression	[11]
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL)	OT50L4XB	ACADV_HUMAN	Decreases Expression	[11]
Peroxisomal multifunctional enzyme type 2 (HSD17B4)	OT8733D7	DHB4_HUMAN	Decreases Expression	[11]
Delta-1-pyrroline-5-carboxylate synthase (ALDH18A1)	OT6W40XU	P5CS_HUMAN	Decreases Expression	[11]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK)	OTNPRM8U	HNRPK_HUMAN	Decreases Expression	[11]
Small ribosomal subunit protein uS9 (RPS16)	OTVGZOB5	RS16_HUMAN	Decreases Expression	[11]
Large ribosomal subunit protein eL30 (RPL30)	OTLQVY1Z	RL30_HUMAN	Increases Expression	[11]
Microtubule-associated protein 1A (MAP1A)	OTHO8K43	MAP1A_HUMAN	Decreases Expression	[11]
Large ribosomal subunit protein eL19 (RPL19)	OT33LM66	RL19_HUMAN	Decreases Expression	[11]
Transcriptional activator protein Pur-alpha (PURA)	OT975ELW	PURA_HUMAN	Increases Expression	[11]
Protein Dr1 (DR1)	OTR081M4	NC2B_HUMAN	Decreases Expression	[11]
Synaptic vesicular amine transporter (SLC18A2)	OTUOMMM6	VMAT2_HUMAN	Affects Binding	[35]
Mitochondrial-processing peptidase subunit alpha (PMPCA)	OT5X1G9Q	MPPA_HUMAN	Increases Expression	[11]
Aspartyl/asparaginyl beta-hydroxylase (ASPH)	OT3KGDEE	ASPH_HUMAN	Increases Expression	[11]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[36]
Translation initiation factor eIF2B subunit epsilon (EIF2B5)	OTV3R4RB	EI2BE_HUMAN	Increases Expression	[11]
Transcription intermediary factor 1-beta (TRIM28)	OTE38OBF	TIF1B_HUMAN	Decreases Expression	[11]
Condensin complex subunit 2 (NCAPH)	OTXOS97C	CND2_HUMAN	Decreases Expression	[11]
Inorganic pyrophosphatase (PPA1)	OTHZK1QB	IPYR_HUMAN	Increases Expression	[11]
Reticulocalbin-1 (RCN1)	OT3JBGAG	RCN1_HUMAN	Decreases Expression	[11]
Splicing factor 3B subunit 4 (SF3B4)	OTGB9OR9	SF3B4_HUMAN	Decreases Expression	[11]
Disks large homolog 2 (DLG2)	OTQ3BD8U	DLG2_HUMAN	Increases Expression	[11]
Striated muscle preferentially expressed protein kinase (SPEG)	OTQXWJR4	SPEG_HUMAN	Increases Expression	[11]
Cryptochrome-1 (CRY1)	OTTGAJT0	CRY1_HUMAN	Decreases Expression	[30]
Histone H2A type 2-C (H2AC20)	OTEIVLM1	H2A2C_HUMAN	Increases Expression	[11]
Tau-tubulin kinase 1 (TTBK1)	OTYW316L	TTBK1_HUMAN	Increases Expression	[11]
Coiled-coil domain-containing protein 121 (CCDC121)	OTWZ4FTT	CC121_HUMAN	Increases Expression	[11]
Nucleoporin p54 (NUP54)	OTHOIRMG	NUP54_HUMAN	Decreases Expression	[11]
Retinol dehydrogenase 11 (RDH11)	OTIND43N	RDH11_HUMAN	Decreases Expression	[11]
Dynein axonemal heavy chain 3 (DNAH3)	OTD2JOKM	DYH3_HUMAN	Increases Expression	[11]
Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 (DHX38)	OTBVB3W5	PRP16_HUMAN	Decreases Expression	[11]
Small ribosomal subunit protein mS31 (MRPS31)	OTB0OBWK	RT31_HUMAN	Increases Expression	[11]
AP-2 complex subunit mu (AP2M1)	OTQCOSFN	AP2M1_HUMAN	Increases Expression	[11]
Probable ATP-dependent RNA helicase DDX27 (DDX27)	OT64NCZ6	DDX27_HUMAN	Increases Expression	[11]
PDZ and LIM domain protein 5 (PDLIM5)	OTLQVV22	PDLI5_HUMAN	Decreases Expression	[11]
Kremen protein 1 (KREMEN1)	OTGJFSAC	KREM1_HUMAN	Increases Expression	[11]
KH domain-containing RNA-binding protein QKI (QKI)	OTTAUGLB	QKI_HUMAN	Increases Expression	[37]
Transcriptional regulator protein Pur-beta (PURB)	OTCDDKYB	PURB_HUMAN	Decreases Expression	[11]
Melanin-concentrating hormone receptor 1 (MCHR1)	OTT57EOE	MCHR1_HUMAN	Affects Binding	[38]
Transmembrane 9 superfamily member 2 (TM9SF2)	OTA0C202	TM9S2_HUMAN	Decreases Expression	[11]
COP9 signalosome complex subunit 4 (COPS4)	OTNK2KS1	CSN4_HUMAN	Decreases Expression	[11]
Histone H2A.J (H2AJ)	OTVA4XTW	H2AJ_HUMAN	Increases Expression	[11]
MKI67 FHA domain-interacting nucleolar phosphoprotein (NIFK)	OT20GHN3	MK67I_HUMAN	Decreases Expression	[11]
ATP-dependent DNA/RNA helicase DHX36 (DHX36)	OT8IGL9Y	DHX36_HUMAN	Decreases Expression	[11]
tRNA:m(4)X modification enzyme TRM13 homolog (TRMT13)	OT2H0MCE	TRM13_HUMAN	Decreases Expression	[11]
Tropomodulin-3 (TMOD3)	OTQPNSTH	TMOD3_HUMAN	Decreases Expression	[11]
Endoplasmic reticulum aminopeptidase 1 (ERAP1)	OT72S99B	ERAP1_HUMAN	Decreases Expression	[11]
Ribosome-binding protein 1 (RRBP1)	OT4ZTPTM	RRBP1_HUMAN	Decreases Expression	[11]
DnaJ homolog subfamily B member 11 (DNAJB11)	OTDDK2SY	DJB11_HUMAN	Increases Expression	[11]
Translocation protein SEC63 homolog (SEC63)	OT1ICPMK	SEC63_HUMAN	Increases Expression	[11]
Cysteine and histidine-rich domain-containing protein 1 (CHORDC1)	OT3W6F1U	CHRD1_HUMAN	Increases Expression	[11]
Unconventional myosin-Vb (MYO5B)	OTCKL3W3	MYO5B_HUMAN	Decreases Expression	[11]
Pre-mRNA-processing factor 19 (PRPF19)	OTQ1STV3	PRP19_HUMAN	Increases Expression	[11]
E3 ubiquitin-protein ligase PDZRN3 (PDZRN3)	OTQ891OS	PZRN3_HUMAN	Decreases Expression	[11]
DNA-binding protein SATB2 (SATB2)	OT2W80XC	SATB2_HUMAN	Decreases Expression	[11]
TRPM8 channel-associated factor 1 (TCAF1)	OTSQQ37P	TCAF1_HUMAN	Decreases Expression	[11]
Talin-2 (TLN2)	OT10QQBC	TLN2_HUMAN	Decreases Expression	[11]
Mitogen-activated protein kinase 14 (MAPK14)	OT5TCO3O	MK14_HUMAN	Increases ADR	[26]
Sodium-dependent serotonin transporter (SLC6A4)	OT6FGDLW	SC6A4_HUMAN	Increases ADR	[26]
Dysbindin (DTNBP1)	OT9UQT2S	DTBP1_HUMAN	Increases Response To Substance	[39]
NADH-ubiquinone oxidoreductase chain 1 (ND1)	OTCLGIXV	NU1M_HUMAN	Increases ADR	[26]
Mitogen-activated protein kinase 8 (MAPK8)	OTEREYS5	MK08_HUMAN	Increases ADR	[26]
Synaptosomal-associated protein 25 (SNAP25)	OTUIQ81Q	SNP25_HUMAN	Affects Response To Substance	[40]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Delirium	DCHQKZL	N. A.	Phase 2	[41]
Advanced Cancers	DCNZ4I9	N. A.	Phase 2	[42]

References

• [1] ClinicalTrials.gov (NCT04715230) Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose (Meth-OD). U.S. National Institutes of Health.
• [2] Lorazepam FDA Label
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5884).
• [4] Haloperidol FDA Label
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 86).
• [6] Sigma-1Rs are upregulated via PERK/eIF2/ATF4 pathway and execute protective function in ER stress. Biochem Biophys Res Commun. 2011 Nov 25;415(3):519-25.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [8] Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
• [9] Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
• [10] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [11] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [12] Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors. Neurochem Res. 2017 Apr;42(4):943-952. doi: 10.1007/s11064-016-2127-2. Epub 2016 Nov 30.
• [13] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [14] A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
• [15] Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004 Aug;56(8):967-75.
• [16] Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
• [17] In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab Dispos. 2001 Dec;29(12):1638-43.
• [18] Use of antidepressant drugs in schizophrenic patients with depression. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.
• [19] Drug Interactions Flockhart Table
• [20] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [21] Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004 Dec;24(6):656-60. doi: 10.1097/01.jcp.0000145340.53417.ca.
• [22] Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox. Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):81-5.
• [23] Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays. Chem Res Toxicol. 2013 Jun 17;26(6):878-95.
• [24] The differential effects of neuroleptic drugs and PACAP on the expression of BDNF mRNA and protein in a human glioblastoma cell line. Acta Neurobiol Exp (Wars). 2017;77(3):205-213.
• [25] The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 3;13(21):3779-82. doi: 10.1016/j.bmcl.2003.07.015.
• [26] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [27] Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J. 2005;5(5):298-304.
• [28] Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci. 2006 Oct 20;7:69.
• [29] Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
• [30] Haloperidol, but not olanzapine, may affect expression of PER1 and CRY1 genes in human glioblastoma cell line. Biol Rhythm Res. 2016 Nov 1;47(6):865-871. doi: 10.1080/09291016.2016.1202379. Epub 2016 Jul 1.
• [31] The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther. 2000 Sep;22(9):1085-96. doi: 10.1016/S0149-2918(00)80086-7.
• [32] Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases. Neuropsychopharmacology. 2006 Apr;31(4):853-65. doi: 10.1038/sj.npp.1300911.
• [33] Effects of different antipsychotics and the antidepressant mirtazapine on glucose transporter mRNA levels in human blood cells. J Psychiatr Res. 2006 Jun;40(4):374-9. doi: 10.1016/j.jpsychires.2005.04.016. Epub 2005 Jul 5.
• [34] Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12.
• [35] Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res. 1994 Mar;22(1-4):219-26. doi: 10.1016/0169-328x(94)90050-7.
• [36] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [37] Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells. BMC Pharmacol. 2009 Mar 31;9:6. doi: 10.1186/1471-2210-9-6.
• [38] No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation. Pharmacogenomics J. 2007 Aug;7(4):275-81. doi: 10.1038/sj.tpj.6500418. Epub 2006 Sep 19.
• [39] The efficacies of clozapine and haloperidol in refractory schizophrenia are related to DTNBP1 variation. Pharmacogenet Genomics. 2009 Jun;19(6):437-46. doi: 10.1097/FPC.0b013e32832b9cfc.
• [40] The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett. 2005 May 6;379(2):81-9. doi: 10.1016/j.neulet.2004.12.037. Epub 2005 Jan 26.
• [41] ClinicalTrials.gov (NCT03743649) Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
• [42] ClinicalTrials.gov (NCT01949662) Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer